华润医药通过认购及转让入股英特集团(000411.SZ)持股达20%
格隆汇7月16日丨英特集团(000411.SZ)公布,公司非公开发行股票已完成,华润医药商业集团有限公司(“华润医药商业”)认购公司非公开发行的股票约4148.999万股。
同时,公司近日收到通知,公司控股股东浙江省国际贸易集团有限公司(“国贸集团”)的子公司浙江省中医药健康产业集团有限公司(“健康产业集团”)、浙江华辰投资发展有限公司(“华辰投资”)通过深圳证券交易所大宗交易系统向华润医药商业转让公司无限售流通股合计约829.80万股。
因此次非公发行股票导致公司总股本增加以及前述大宗交易减持行为,国贸集团及其一致行动人合计持有公司股份由54.65%下降为42.21%,华润医药商业持有公司20%股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.